Cardiac Screening Cost-Effectiveness Model (Population-Level)
Model inputs
Enter population, screening performance, treatment, cost, and health-outcome assumptions. Use one currency and a consistent costing perspective.
About this model
This deterministic population-level calculator explores how prevalence, screening performance, treatment costs, event risk, and health-outcome assumptions may affect estimated costs and QALYs.
What it calculates
- Expected true-positive, false-negative, false-positive, and true-negative initial screening results.
- Screening and confirmatory costs, plus treatment costs over the entered horizon.
- Approximate events prevented, event costs averted, QALYs gained, and an ICER.
- A comparison of the estimated ICER with the entered willingness-to-pay threshold.
Key assumptions
- Initial test sensitivity and specificity are applied to the stated prevalence.
- Every positive initial screen incurs confirmatory testing cost; confirmatory accuracy is not represented.
- Screening true positives are treated as the therapy group because confirmatory-test accuracy and treatment uptake are not input parameters.
- Annual event risk is constant; competing risks and adverse effects are omitted.
- Discounting uses an average-factor approximation, not a year-by-year state-transition or cohort simulation.
Recommended use
Use for preliminary scenario exploration and teaching. A real programme assessment should define comparators and perspective, use local costs, model confirmatory-test accuracy and treatment uptake, include harms and competing mortality, and evaluate parameter and structural uncertainty.
Method and references
These sources support general economic-evaluation methods and screening principles. They do not validate this calculator's equations or establish cost-effectiveness of a specific cardiac screening strategy.
Clinical notes
Document key findings and keep a structured record for your own reference.
My notes
Review, edit, or remove notes saved in this browser.
Report an issue
Your feedback helps us improve the reliability and usability of this clinical tool.